Meropenem/tazobactam

Drug Profile

Meropenem/tazobactam

Alternative Names: Tazobactam/meropenem

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Aqua Vitoe Laboratories
  • Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Gram-negative infections

Most Recent Events

  • 18 Feb 2016 No development reported - Phase-III for Gram-negative infections in India (IV)
  • 05 May 2013 Aqua Vitoe Laboratories completes a phase III trial for Gram-negative infections in India (IV)
  • 05 Nov 2012 Phase-III clinical trials in Gram-negative infections in India (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top